Enhanced EIF4A activity is associated with malignant proliferation and the survival of tumour cells (5, 6, 7), and small-molecule inhibitors of EIF4A have been developed as anti-cancer drugs (7, 8, 9, 10, 11). This evidence concerns the gene EIF4A2 and cancer.